Please use this identifier to cite or link to this item: http://repository.tma.uz/xmlui/handle/1/9416
Full metadata record
DC FieldValueLanguage
dc.contributor.authorZaripov S.I.-
dc.date.accessioned2023-11-26T15:19:19Z-
dc.date.available2023-11-26T15:19:19Z-
dc.date.issued2023-
dc.identifier.citationToshkenten_US
dc.identifier.issn2181-3183-
dc.identifier.urihttp://repository.tma.uz/xmlui/handle/1/9416-
dc.description.abstractSystemic sclerosis (M34.0) is a polysyndromic autoimmune disease characterized by progressive fibrosis of the skin, musculoskeletal system, internal organs (lungs, kidneys, heart, digestive system) and vasospastic disturbances.It occurs in around 30 people per million population per year and there are an estimated 125,000 active cases in the United States and perhaps 2.5 million worldwide. Although systemic sclerosis is infrequent, it has a high morbidity and mortality and serious life threatening complications. The main marker of an abnormal immune response is circulating autoantibodies, which are found in more than 95% of patients with systemic sclerosis. It is important to study the clinical, immunological, diagnostic and prognostic significance of autoantibodies.en_US
dc.language.isoenen_US
dc.relation.ispartofseriesУДК;616.12-008.46-06:616.12-008.331.1- 616.5-004.1-
dc.subjectSystemic sclerosis, anti-nuclear antibodies, fibrillarin-(U3-RNP), AFA- anti-fibrillarin antibodies, Raynaud's phenomenonen_US
dc.titlePathophysiological and clinical significance of anti-nuclear antibodies in systemic sclerosisen_US
dc.typeArticleen_US
Appears in Collections:Thesis, Articles

Files in This Item:
File Description SizeFormat 
42. MedUnion Zaripov S.pdfPathophysiological and clinical significance of anti-nuclear antibodies in systemic sclerosis312.9 kBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.